UY32364A - Derivados oxadiazole como agonistas de los receptores de esfingosina-1-fosfato (s1p1) - Google Patents
Derivados oxadiazole como agonistas de los receptores de esfingosina-1-fosfato (s1p1)Info
- Publication number
- UY32364A UY32364A UY0001032364A UY32364A UY32364A UY 32364 A UY32364 A UY 32364A UY 0001032364 A UY0001032364 A UY 0001032364A UY 32364 A UY32364 A UY 32364A UY 32364 A UY32364 A UY 32364A
- Authority
- UY
- Uruguay
- Prior art keywords
- alkyl
- nrarb
- carboxyalkyl
- haloalkyl
- hydroxyalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Compuestos de fórmula (I), sales o N-óxidos de los mismos farmacéuticamente aceptables, donde A : - N-, -O-y -S-; B y C : -N- y -O-, al menos 2 de A, B y C sean N; G1 : H, y -CRc-, Rc es H, halógeno, alquilo C1-4, o alcoxi C1-4; R1 : H, alquilo C1-4, alcoxi C1-4, cicloalquilo C3-4, y -NRdRe Rd y Re son independientemente H o alquilo C1-4; R2 y R3 : H, alquilo C1-4; R4 , R5 y R7 son independientemente H, halógeno, alquilo C1-4, alcoxi C1-4 y haloalquilo C1-4; R6 : alquilo C1-4 o hidroxialquio C1-4; o R6 es : -S(O)2-NRaRb, -(CRfRg)n-(CRhRi)x-(CRjRk)y-NRaRb, -(CH2)n-NRaRb, -(CH2)n-COOH, -(CH2)n-NRa-CO-Rb', -(CH2)n-NRa-(CH2)p-(NH)q-SO-CH3y - (CH2)n-CO-NRaRb, n,p,x e y, son enteros 0 a 3, q es 0 o 1, Rf, Rg, Rh, Ri, Rj y Rk independientemente H, halógeno, Rb' : metilsulfonilo, alquilo C1-4, hidroxiaquilo C1-4, carboxialquilo C1-4, y haloalquilo C1-4, o Ra y Rb : H, metilsulfonilo, alquilo C1-4, hidroxialquilo C1-4, carboxialquilo C1-4, y haloalquilo C1-4, o Ra y Rb con el N uni do forman heterocíclico saturado, 4 a 6 miembros teniendo, 1 o 2 átomos de N y sustituido con carboxilo o carboxialquilo C1-4; o Rc con R6 forman ani llo carbocíclico C5-8 opcionalmente sustituido con -NHR´ y R´ es H o carboxialquilo C1-4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09382004A EP2210890A1 (en) | 2009-01-19 | 2009-01-19 | Oxadiazole derivatives as S1P1 receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32364A true UY32364A (es) | 2010-02-26 |
Family
ID=40568602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032364A UY32364A (es) | 2009-01-19 | 2009-12-23 | Derivados oxadiazole como agonistas de los receptores de esfingosina-1-fosfato (s1p1) |
Country Status (17)
Country | Link |
---|---|
US (1) | US20110274657A1 (es) |
EP (2) | EP2210890A1 (es) |
JP (1) | JP2012515182A (es) |
KR (1) | KR20110110198A (es) |
CN (1) | CN102282144A (es) |
AR (1) | AR075022A1 (es) |
AU (1) | AU2010205825A1 (es) |
BR (1) | BRPI1005153A2 (es) |
CA (1) | CA2748394A1 (es) |
EA (1) | EA201101089A1 (es) |
EC (1) | ECSP11011200A (es) |
IL (1) | IL213630A0 (es) |
MX (1) | MX2011007455A (es) |
SG (1) | SG172452A1 (es) |
TW (1) | TW201028407A (es) |
UY (1) | UY32364A (es) |
WO (1) | WO2010081692A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE030235T2 (en) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corp | Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors |
EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
EA020494B1 (ru) | 2009-05-22 | 2014-11-28 | Инсайт Корпорейшн | 3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ]ОКТАН- ИЛИ ГЕПТАННИТРИЛ КАК JAK-ИНГИБИТОРЫ |
US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
MX347851B (es) | 2010-03-10 | 2017-05-16 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
EP3087972A1 (en) | 2010-05-21 | 2016-11-02 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
US8629282B2 (en) | 2010-11-03 | 2014-01-14 | Bristol-Myers Squibb Company | Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases |
EP2640725B1 (en) | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
SG190839A1 (en) | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
EP2455081A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of crohn's disease |
KR102024948B1 (ko) | 2011-02-18 | 2019-11-04 | 노파르티스 파르마 아게 | mTOR/JAK 저해제 병용 요법 |
AR086983A1 (es) | 2011-06-20 | 2014-02-05 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
WO2013023119A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | JAK P13K/mTOR COMBINATION THERAPY |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
WO2013113716A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113776A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113720A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
CN104220427A (zh) | 2012-02-03 | 2014-12-17 | 巴斯夫欧洲公司 | 杀真菌嘧啶化合物 |
EA201400858A1 (ru) | 2012-02-03 | 2015-01-30 | Басф Се | Фунгицидные пиримидиновые соединения |
WO2013113791A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113773A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
KR20220162825A (ko) | 2012-11-15 | 2022-12-08 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
UY35338A (es) | 2013-02-21 | 2014-08-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen |
AU2014225938B2 (en) | 2013-03-06 | 2018-07-19 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
KR20160045081A (ko) | 2013-08-07 | 2016-04-26 | 인사이트 코포레이션 | Jak1 억제제용 지속 방출 복용 형태 |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
UY36274A (es) | 2014-08-20 | 2016-02-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
US11192886B2 (en) * | 2016-07-22 | 2021-12-07 | Medshine Discovery Inc. | S1P1 agonist and application thereof |
TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
TWI797242B (zh) | 2018-01-30 | 2023-04-01 | 美商英塞特公司 | 製備jak抑制劑之方法及中間物 |
MX2022012285A (es) | 2018-03-30 | 2023-08-15 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
WO2021101854A1 (en) | 2019-11-19 | 2021-05-27 | Trevena, Inc. | Compounds and methods of preparing compounds s1p1 modulators |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
JP2024506387A (ja) * | 2021-02-10 | 2024-02-13 | アイカーン スクール オブ メディスン アット マウント サイナイ | 腎線維症を治療するためのオキサジアゾリルジヒドロピラノ[2,3‐b]ピリジン系HIPK2阻害剤 |
WO2024031041A2 (en) * | 2022-08-05 | 2024-02-08 | Icahn School Of Medicine At Mount Sinai | Oxygen-containing heterocyclic compound and use thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994000943A1 (en) | 1992-06-23 | 1994-01-06 | Motorola, Inc. | Multi-modulation scheme compatible radio |
DE69617431T2 (de) | 1995-06-21 | 2002-08-01 | Asta Medica Ag | Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator |
DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
CA2483594C (en) | 2002-05-16 | 2011-02-15 | Novartis Ag | Use of edg receptor binding agents in cancer |
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
WO2004103279A2 (en) * | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
EP1484057A1 (en) | 2003-06-06 | 2004-12-08 | Aventis Pharma Deutschland GmbH | Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain |
AU2004271804B2 (en) | 2003-09-12 | 2011-01-06 | Newron Sweden Ab | Treatment of disorders of the nervous system |
US20070043014A1 (en) * | 2003-10-01 | 2007-02-22 | Merck & Co., Inc. | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
WO2005058848A1 (en) * | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
US20080306124A1 (en) * | 2005-06-08 | 2008-12-11 | Rainer Albert | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands |
GB0601744D0 (en) * | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
AU2007209961A1 (en) | 2006-01-27 | 2007-08-09 | University Of Virginia Patent Foundation | Method for treatment of neuropathic pain |
TWI389683B (zh) | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
US8318812B2 (en) | 2006-06-02 | 2012-11-27 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of lymphoid malignancies |
GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
CN101553216B (zh) | 2006-08-17 | 2012-03-21 | 芝加哥大学 | 炎性疾病的治疗 |
-
2009
- 2009-01-19 EP EP09382004A patent/EP2210890A1/en not_active Withdrawn
- 2009-12-23 UY UY0001032364A patent/UY32364A/es not_active Application Discontinuation
-
2010
- 2010-01-13 TW TW099100840A patent/TW201028407A/zh unknown
- 2010-01-14 JP JP2011545678A patent/JP2012515182A/ja active Pending
- 2010-01-14 AU AU2010205825A patent/AU2010205825A1/en not_active Abandoned
- 2010-01-14 US US13/144,377 patent/US20110274657A1/en not_active Abandoned
- 2010-01-14 CN CN2010800049696A patent/CN102282144A/zh active Pending
- 2010-01-14 EP EP10700383A patent/EP2387571A1/en not_active Withdrawn
- 2010-01-14 SG SG2011048329A patent/SG172452A1/en unknown
- 2010-01-14 MX MX2011007455A patent/MX2011007455A/es not_active Application Discontinuation
- 2010-01-14 WO PCT/EP2010/000158 patent/WO2010081692A1/en active Application Filing
- 2010-01-14 EA EA201101089A patent/EA201101089A1/ru unknown
- 2010-01-14 CA CA2748394A patent/CA2748394A1/en not_active Abandoned
- 2010-01-14 BR BRPI1005153A patent/BRPI1005153A2/pt not_active IP Right Cessation
- 2010-01-14 KR KR1020117016785A patent/KR20110110198A/ko not_active Application Discontinuation
- 2010-01-15 AR ARP100100089A patent/AR075022A1/es unknown
-
2011
- 2011-06-16 IL IL213630A patent/IL213630A0/en unknown
- 2011-07-13 EC EC2011011200A patent/ECSP11011200A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010081692A1 (en) | 2010-07-22 |
AR075022A1 (es) | 2011-03-02 |
EP2210890A1 (en) | 2010-07-28 |
EA201101089A1 (ru) | 2012-02-28 |
MX2011007455A (es) | 2011-08-03 |
TW201028407A (en) | 2010-08-01 |
JP2012515182A (ja) | 2012-07-05 |
EP2387571A1 (en) | 2011-11-23 |
CA2748394A1 (en) | 2010-07-22 |
AU2010205825A1 (en) | 2011-07-07 |
IL213630A0 (en) | 2011-07-31 |
US20110274657A1 (en) | 2011-11-10 |
KR20110110198A (ko) | 2011-10-06 |
SG172452A1 (en) | 2011-07-28 |
ECSP11011200A (es) | 2011-08-31 |
CN102282144A (zh) | 2011-12-14 |
BRPI1005153A2 (pt) | 2019-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32364A (es) | Derivados oxadiazole como agonistas de los receptores de esfingosina-1-fosfato (s1p1) | |
ES2515095T3 (es) | Derivados de adamantil acetamida como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
CY1122863T1 (el) | Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα | |
AR064197A1 (es) | Derivados de pirimidina y piridina inhibidores de la proteina quinasa | |
RU2008102993A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
ES2570756T3 (es) | Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa | |
PE20121526A1 (es) | Compuestos policiclicos heterociclicos como inhibidores del virus de la hepatitis c | |
ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
AR081075A1 (es) | Derivados de imidazo[1,2-c]pirimidina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias. | |
AR050953A1 (es) | Compuestos de sulfonamida inhibidores de los receptores de cck1/cck2 duales | |
AR076170A1 (es) | Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. | |
CO5700757A2 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
DOP2010000194A (es) | Derivados de oxadiazol activos sobre fosfato de esfingosina-1 | |
CO6190626A2 (es) | Compuestos y composiciones como inhibidores de proteasa activadora de canal | |
AR044078A1 (es) | Dihidroquinazolinas sustituidas | |
AR089175A1 (es) | Inhibidores de pak para el tratamiento de trastornos de proliferacion celular | |
EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
AR061806A1 (es) | Derivados de alquilpiridazina como inhibidores de 11b-hsd1 (t2d) | |
PE20100737A1 (es) | Nuevos compuestos | |
CO6160330A2 (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3 | |
AR060033A1 (es) | Utilizacion de antagonistas de receptor crf1 para preparar un farmaco para tratar del sindrome metabolico y/o la obesidad y/o la dislipoproteinemia | |
JOP20200197A1 (ar) | مثبطات أرجيناز وطرق لاستخدامها | |
MXPA05008672A (es) | Derivados de xantina sustituida con sulfonamida para el uso como inhibidores de fosfoenolpiruvato-carboxicinasa (pepck). | |
ECSP099565A (es) | Compuesto de 2-amino pirimidina | |
CO6321266A2 (es) | Inhibidores limk2 compuestos de los cuales estan hechos y metodologia de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20190121 |